SecBot SecBot
S-3ASR ·Filed Jun 18, 2026

IOVA

IOVANCE BIOTHERAPEUTICS, INC.
NEUTRAL
Impact 5/10
Horizonweeks Processed5mo ago SEC0001104659-26-075778
Notable filing: S-3ASR
Actionable Insight • Neutral

The ATM replenishment is routine for a commercial-stage biotech with ongoing cash needs and was expected. The near-term overhang is minimal given the modest remaining capacity relative to market cap. Watch for actual sales pace and any use of the broader shelf for debt or equity, if a large follow-on or convertible is announced in coming weeks, the impact would be more significant. For now, this is a neutral financing event consistent with Iovance's communicated strategy.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$4.06
T+0 close · Jun 18, 2026 · via day close
Latest settled
+130.54%
T+60 · $9.36
Vs SPY
+128.80%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 22 $4.06entry
  2. T+1 · 5mo ago +9.36%α +10.81% · $4.44
  3. T+5 · 5mo ago +4.68%α +6.75% · $4.25
  4. T+20 · 4mo ago +23.15%α +23.30% · $5.00
  5. T+60 · 2mo ago +130.54%α +128.80% · $9.36
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Iovance Biotherapeutics filed an S-3ASR shelf registration, enabling it to offer and sell up to $89.7 million in common stock via an existing ATM agreement with Jefferies. The company has already drawn $260.3 million from the $350 million facility, and the remaining capacity is being refinanced under this new shelf. With a market cap of $1.8B, the potential dilution from the full $89.7M offering is roughly 5% of current shares outstanding, which is moderate. The 10-Q shows cash and investments of $425.7M in net tangible book value, but the company is pre-tax profitable and still burning cash on R&D and commercial launch costs, making this a capital-raising event to extend runway rather than a distress signal.

Key Facts

  • S-3ASR filed for an indeterminate amount of common stock, preferred stock, debt, warrants, units, and rights, with an immediate ATM component of $89.65M in common stock.
  • The ATM is a replenishment of a prior $350M facility: $260.35M already sold, leaving $89.65M remaining.
  • As of March 31, 2026, the company had 438.1M shares outstanding; full draw of $89.65M at $3.93/share would add ~22.8M shares, diluting by ~5.2%.
  • Net tangible book value was $425.7M ($0.97/share) at Q1 2026 end; pro forma after maximum ATM draw would be ~$513.3M ($1.11/share).
  • Iovance has $89.65M in ATM capacity remaining; the filing also creates a shelf for future debt or equity issuances of any size at management's discretion.
  • 10-Q shows $0 revenue in Q1 2026 (same as prior year), net loss of $107M, and cash/investments of ~$425M, a 2-year runway at current burn, but the draw extends coverage for ongoing trials and commercial launch of Amtagvi.

Financial Impact

Up to $89.65 million in common stock issuance under an ATM, representing ~5.2% dilution at current prices ($3.93/share). Proceeds earmarked for commercial launch, clinical trials, and general corporate purposes.

dilutioncash_runway

Risk Factors

  • Sale of the full $89.65M in ATM shares would dilute existing holders by ~5.2%.
  • Future debt or equity offerings under the broader S-3ASR (beyond the current ATM) could increase leverage or further dilute.
  • Proceeds are not tied to a specific catalyst, and management has broad discretion on use, creating execution risk if cash burn continues without revenue inflection.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

DocumentAccession Number
S-3ASR Filing (Primary)0001104659-26-075778
Document: iova-20260618xs3asr.htm0001104659-26-075778

Track record

21 reports on IOVA

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +121.97% at T+60 after the Jun 10, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $8.08 Now $7.55 −6.56% settles Dec 9
  2. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $8.04 Now $7.55 −6.09% settles Dec 7
  3. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $7.74 Now $7.55 −2.45% settles Dec 4
  4. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $8.70 Now $7.55 −13.22% settles Dec 3
  5. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $8.48 Now $7.55 −10.97% settles Nov 30
  6. Oct 28, 202619d ago Press Release Bullish 7/10 Entry $9.56 Now $7.55 −21.03% settles Nov 27
  7. Oct 5, 20266w ago 8-K Neutral 4/10 Entry $12.96 to $8.65 Now $7.55 −41.74% ▼ −33.25% −30.34% vs SPY
  8. Oct 2, 20266w ago 3 Neutral 2/10 Entry $14.15 to $7.93 Now $7.55 −46.64% ▼ −43.99% −41.42% vs SPY
  9. Sep 29, 20266w ago 8-K Bullish 6/10 Entry $14.45 to $14.58 Now $7.55 −47.75% ▲ +0.90% +0.19% vs SPY
  10. Aug 21, 202612w ago Press Release Neutral 2/10 Entry $8.06 to $10.64 Now $7.55 −6.33% ▲ +32.01% +30.70% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 5h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 18, 2026